CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Recruiting · NCT04704323 · Registry updated 2025-07-17Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 | 2025-07-17 | NCT04704323 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Catapult Therapeutics | 1 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Dana-Farber Cancer Institute | Boston | United States | 626 |
| Duke University | Durham | United States | 91 |
| Hospital Universitario de la Princesa | Madrid | Spain | 53 |
| Hospital Universitario Marqués de Valdecilla | Santander | Spain | 46 |